Establishment Labs Holdings Inc. (NASDAQ:ESTA) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) have been given an average recommendation of “Moderate Buy” by the nine brokerages that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $87.1429.

A number of analysts recently weighed in on the stock. Wall Street Zen cut shares of Establishment Labs from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. BTIG Research boosted their target price on shares of Establishment Labs from $88.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Citigroup restated a “neutral” rating on shares of Establishment Labs in a research note on Wednesday, May 6th. Stephens lifted their price objective on Establishment Labs from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Finally, Mizuho lifted their price objective on Establishment Labs from $90.00 to $100.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th.

Insider Transactions at Establishment Labs

In other Establishment Labs news, Director Quiros Juan Jose Chacon sold 105,000 shares of Establishment Labs stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $75.42, for a total value of $7,919,100.00. Following the completion of the transaction, the director owned 927,504 shares in the company, valued at approximately $69,952,351.68. The trade was a 10.17% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders sold 330,000 shares of company stock valued at $22,854,538. Insiders own 9.99% of the company’s stock.

Institutional Trading of Establishment Labs

Hedge funds and other institutional investors have recently modified their holdings of the stock. KBC Group NV acquired a new stake in shares of Establishment Labs in the first quarter valued at approximately $28,000. Quarry LP bought a new position in shares of Establishment Labs in the 3rd quarter valued at about $34,000. Kestra Advisory Services LLC bought a new position in shares of Establishment Labs in the 4th quarter valued at about $47,000. State of Wyoming bought a new position in shares of Establishment Labs in the 3rd quarter valued at about $71,000. Finally, Osaic Holdings Inc. boosted its stake in shares of Establishment Labs by 900.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after purchasing an additional 1,800 shares during the last quarter. Institutional investors and hedge funds own 72.91% of the company’s stock.

Establishment Labs Trading Down 3.5%

Establishment Labs stock opened at $82.14 on Friday. The business has a 50 day moving average price of $68.81 and a two-hundred day moving average price of $69.17. The company has a quick ratio of 1.91, a current ratio of 2.96 and a debt-to-equity ratio of 16.82. The stock has a market cap of $2.42 billion, a price-to-earnings ratio of -55.13 and a beta of 1.11. Establishment Labs has a 12 month low of $33.35 and a 12 month high of $86.00.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.10). The firm had revenue of $59.88 million during the quarter, compared to analyst estimates of $57.40 million. Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 218.77%. The company’s revenue was up 44.7% on a year-over-year basis. During the same period last year, the company earned ($0.70) EPS. As a group, equities analysts forecast that Establishment Labs will post -1.07 EPS for the current year.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.